Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Mendus Q1: CEO Interview

By Jesper HagmanCommunity Manager
Mendus

Immunotherapy remains a game-changer in the rapidly evolving landscape of cancer treatment. Leading this wave of innovation is Mendus, which released its Q1 report yesterday (6/5). To discuss the report and key developments from the quarter, we spoke with CEO Erik Manting in an exclusive interview.

Watch the Q1 presentation from Mendus here. 

Följ oss på:

  • X (Twitter)
  • Instagram
  • TikTok

Du är hjärtligt välkommen att ansluta dig till vår kostnadsfria community och delta i heta aktiediskussioner på forumet

Stay up to date
Company management interviews

Recent videos

Talenom - Planned demerger and strategies of Talenom and Easor
18.12.2025 klo 12.00 Talenom
Investing in the life science sector
18.12.2025 klo 08.47
Life Science Companies as Investments | Life Science Night Dec. 9, 2025
16.12.2025 klo 09.30 Aiforia Technologies
Truecaller, Webcast, Press Conference, 2025
15.12.2025 klo 14.00 Truecaller
Herantis Pharma as an Investment | Life Science Night Dec 9, 2025
15.12.2025 klo 14.00 Herantis Pharma
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.